News and Insights
The latest news and insights from Genoa Healthcare.
- Clinical Insights
- Webinar
Understanding Tardive Dyskinesia: What you need to know
Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...
- Apr 11th, 2024
- Clinical Insights
March 2024 drug trend report
Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to...
- Mar 13th, 2024
- Clinical Insights
February 2024 drug trend report
Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to...
- Feb 1st, 2024
- Clinical Insights
Uzedy™: Long-acting injection for the treatment of schizophrenia
Learn more about this new treatment option for adults living with schizophrenia Genoa is here to help keep you informed on the latest in behavioral health medications. Read on to...
- Jan 31st, 2024
- Clinical Insights
Brixadi®: 3 things to know about the buprenorphine treatment option
Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...
- Dec 6th, 2023
- Clinical Insights
November 2023 drug trend report
Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview of the latest and connect with your local...
- Nov 1st, 2023
- Clinical Insights
September 2023 drug trend report
Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Brixadi™ Zurzuvae™ (zuranolone) Generic drug...
- Sep 1st, 2023
- Clinical Insights
Caring for those with treatment-resistant depression
Genoa Healthcare® can partner with you to improve outcomes for your patients living with TRD. Connect with us to get started today. One in three adults with major depressive disorder...
- Aug 9th, 2023
- Clinical Insights
4 things to know about Spravato® (Intranasal esketamine)
Looking for information on Spravato®? Here are four things you should know. Spravato®: What, why and how? Spravato® is an FDA-approved nasal spray indicated for the treatment of treatment-resistant depression...
- Aug 9th, 2023
- Clinical Insights
August 2023 drug trend report
Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Uzedy Abilify Asimtuffii Brixadi Generic...
- Aug 2nd, 2023